BRCA1 and ovarian carcinoma: BRCA1/2 germline mutations are most commonly seen in breast and ovarian cancer patients who benefit from treatment with PARP inhibitors (PARPis) or platinum compounds, but BRCA1-Δ11q splice variants lacking the majority of exon 11 contribute to therapeutic resistance (18, 19).